StocksFundsScreenerSectorsWatchlists
RXST

RXST - RxSight, Inc. Stock Price, Fair Value and News

51.81USD+1.14 (+2.25%)Delayed as of 28 Mar 2024, 11:55 am ET

Market Summary

RXST
USD51.81+1.14
Delayedas of 28 Mar 2024, 11:55 am
2.25%

RXST Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

RXST Stock Price

View Fullscreen

RXST RSI Chart

RXST Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-38.56

Price/Sales (Trailing)

21.04

EV/EBITDA

-45.25

Price/Free Cashflow

-40.39

RXST Price/Sales (Trailing)

RXST Profitability

EBT Margin

-54.55%

Return on Equity

-30.31%

Return on Assets

-26.63%

Free Cashflow Yield

-2.48%

RXST Fundamentals

RXST Revenue

Revenue (TTM)

89.1M

Rev. Growth (Yr)

77.64%

Rev. Growth (Qtr)

28.74%

RXST Earnings

Earnings (TTM)

-48.6M

Earnings Growth (Yr)

41.21%

Earnings Growth (Qtr)

26.08%

Breaking Down RXST Revenue

52 Week Range

16.1552.08
(Low)(High)

Last 7 days

2.9%

Last 30 days

-11.6%

Last 90 days

22.5%

Trailing 12 Months

225%

How does RXST drawdown profile look like?

RXST Financial Health

Current Ratio

8.06

RXST Investor Care

Shares Dilution (1Y)

9.51%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202357.6M67.0M76.6M89.1M
202228.1M34.5M41.3M49.0M
202116.7M18.6M20.6M22.6M
202000014.7M

Tracking the Latest Insider Buys and Sells of RxSight, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 01, 2024
thunen shelley b
sold
-563,726
56.3726
-10,000
chief financial officer
Mar 01, 2024
thunen shelley b
acquired
155,983
15.5983
10,000
chief financial officer
Feb 16, 2024
goldshleger ilya
acquired
230,400
23.04
10,000
chief operating officer
Feb 16, 2024
goldshleger ilya
sold
-555,000
55.5
-10,000
chief operating officer
Feb 15, 2024
goldshleger ilya
sold
-535,000
53.5
-10,000
chief operating officer
Feb 15, 2024
goldshleger ilya
acquired
230,400
23.04
10,000
chief operating officer
Feb 14, 2024
tammenoms bakker juliet
bought
205,153
51.2883
4,000
-
Feb 14, 2024
goldshleger ilya
sold
-260,000
52.00
-5,000
chief operating officer
Feb 14, 2024
goldshleger ilya
acquired
115,200
23.04
5,000
chief operating officer
Feb 12, 2024
tammenoms bakker juliet
bought
201,520
50.3799
4,000
-

1–10 of 50

Which funds bought or sold RXST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
3.49
19,842,300
59,835,300
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
200
5,965,970
7,753,050
-%
Mar 01, 2024
READYSTATE ASSET MANAGEMENT LP
new
-
728,179
728,179
0.03%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
4.5
192,646
569,802
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-628,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
131
1,693,000
2,417,000
-%
Feb 15, 2024
Circle Wealth Management, LLC
unchanged
-
2,059,890
6,681,790
0.17%
Feb 15, 2024
Farther Finance Advisors, LLC
reduced
-90.00
-955
161
-%
Feb 15, 2024
Legal & General Group Plc
added
20.5
370,063
868,735
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
2,770,190
2,770,190
-%

1–10 of 46

Are Funds Buying or Selling RXST?

Are funds buying RXST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RXST
No. of Funds

Unveiling RxSight, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ra capital management, l.p.
9.5%
3,404,285
SC 13G/A
Feb 14, 2024
lord, abbett & co. llc
5.51%
1,977,000
SC 13G
Feb 12, 2024
artisan partners limited partnership
6.7%
2,395,672
SC 13G
Jan 29, 2024
blackrock inc.
5.8%
2,076,470
SC 13G
Aug 18, 2023
longitude capital partners ii, llc
2.8%
994,313
SC 13D/A
Jun 05, 2023
longitude capital partners ii, llc
4.4%
1,491,463
SC 13D/A
Feb 14, 2023
orbimed advisors llc
3.3%
923,733
SC 13G/A
Feb 14, 2022
wolfen richard m.
6.7%
1,827,349
SC 13G
Feb 14, 2022
rxsight i, llc
7.60%
2,016,778
SC 13G
Feb 14, 2022
tamer anthony
7.34%
2,010,037
SC 13G

Recent SEC filings of RxSight, Inc.

View All Filings
Date Filed Form Type Document
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 01, 2024
144
Notice of Insider Sale Intent
Feb 29, 2024
S-8
Employee Benefits Plan
Feb 28, 2024
10-K
Annual Report
Feb 28, 2024
8-K
Current Report
Feb 16, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to RxSight, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

RxSight, Inc. News

Latest updates
Simply Wall St24 Mar 202403:05 pm
MarketBeat19 Mar 202408:17 pm
InvestorsObserver19 Mar 202407:40 pm
Moneyshow.com04 Mar 202408:00 am

RxSight, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Revenue28.7%28,579,50022,199,00020,810,00017,489,00016,088,00012,615,00011,360,0008,942,0008,426,0005,786,0004,897,0003,484,0003,827,0004,170,0002,706,000
Gross Profit28.6%17,653,50013,731,00012,015,00010,366,0007,422,5005,356,0004,788,0003,761,0002,869,0001,341,000-812,0001,119,000-720,000-474,000
Operating Expenses8.6%28,505,00026,243,00025,640,00023,463,00022,412,50021,314,00020,580,00020,339,00017,532,00014,453,00013,065,00012,254,000-9,626,0008,333,000
  S&GA Expenses10.6%21,164,00019,142,00018,239,00016,255,00015,731,00014,926,00014,388,00013,620,00011,616,0009,076,0006,502,0005,611,000-3,825,0003,249,000
  R&D Expenses3.4%7,341,0007,101,0007,401,0007,208,0006,681,5006,388,0006,192,0006,719,0005,916,0005,377,0006,563,0006,643,000-5,801,0005,084,000
EBITDA Margin23.5%-0.46-0.60-0.74-0.92-1.18-1.41-1.57-1.83-1.821.551.721.92---
Interest Expenses-98.5%3,500230,0001,568,0001,507,0001,451,0001,299,0001,136,0001,060,0001,079,0001,079,000826,000698,000-3,0004,000
Income Taxes-250.0%-18,00012,00026,000-5,000--4,0002,000-4,0003,0007,000-8,00040,000
Earnings Before Taxes25.9%-9,195,000-12,403,000-13,778,000-13,212,000-15,605,000-16,818,000-16,732,000-17,592,000-15,731,500-12,677,000-13,474,000-6,798,000-30,672,000-12,842,000
EBT Margin24.0%-0.55-0.72-0.89-1.08-1.36-1.62-1.82-2.12-2.151.341.481.66---
Net Income26.1%-9,177,000-12,415,000-13,804,000-13,212,000-15,610,000-16,818,000-16,732,000-17,596,000-15,733,500-12,673,000-13,477,000-6,805,00026,295,00030,664,000-12,882,000
Net Income Margin24.1%-0.55-0.72-0.89-1.08-1.36-1.62-1.82-2.12-2.16-0.321.972.24---
Free Cashflow-14.6%-9,892,000-8,635,000-9,369,000-18,511,000-14,216,000-15,768,000-15,904,000-15,355,000-9,087,000-14,009,000-12,802,000-10,750,000---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets0.4%18318219520315015616717719320495.00101
  Current Assets0.3%16816818018813513915016117618676.0082.00
    Cash Equivalents-1.7%10.0010.009.0011.0012.0010.0025.0025.0025.0069.0042.0014.00
  Inventory-7.9%17.0019.0018.0018.0015.0015.0012.008.008.009.009.008.00
  Net PPE5.6%11.0010.0011.0010.0010.0011.0011.0011.0011.0012.0013.0013.00
Liabilities8.9%22.0020.0038.0058.0060.0060.0057.0054.0054.0053.0055.0045.00
  Current Liabilities10.4%21.0019.0017.0015.0017.0016.0013.0011.0011.009.0011.0012.00
  Long Term Debt---20.0040.0040.0040.0040.0040.0040.0040.0040.0024.00
Shareholder's Equity-0.7%16016115714590.0096.00110123138151--
  Retained Earnings-1.6%-594-585-573-559-546-530-513-496-479-463-450-430
  Additional Paid-In Capital1.1%755747730704636626624620618614138-
Shares Outstanding0.8%36.0036.0035.0034.0028.0028.0028.0027.0027.0019.004.00-
Float---869---310-236---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-4.0%-8,301-7,982-7,546-17,764-13,854-15,188-14,823-14,985-8,722-13,755-11,979-10,252---
  Share Based Compensation8.7%4,4254,0713,9553,2952,9622,8822,9042,6492,9172,0131,4061,239---
Cashflow From Investing-73.6%4,56617,2754,395-48,36510,40556043,844-14,859-35,346-80,24119,17714,503---
Cashflow From Financing143.3%3,562-8,23489165,3056,307-455578-98.00404120,54710,2476,144---

RXST Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]  
Revenue from contracts with customers$ 89,077$ 49,005
Cost of sales35,31227,677
Gross profit53,76521,328
Operating expenses:  
Selling, general and administrative74,79958,665
Research and development29,05125,981
Total operating expenses103,85084,646
Loss from operations(50,085)(63,318)
Other income (expense), net:  
Interest expense(3,308)(4,946)
Interest and other income6,5741,517
Loss on extinguishment of term loan(1,769)0
Loss before income taxes(48,588)(66,747)
Income tax expense209
Net loss(48,608)(66,756)
Other comprehensive income (loss)  
Unrealized gain (loss) on short-term investments83(66)
Foreign currency translation income (loss)7(9)
Total other comprehensive income (loss)9075
Comprehensive loss$ (48,518)$ (66,831)
Net loss per share:  
Attributable to common stock, basic$ (1.41)$ (2.41)
Attributable to common stock, diluted$ (1.41)$ (2.41)
Weighted-average shares outstanding used in computing net loss per share:  
Attributable to common stock, basic34,455,11127,661,982
Attributable to common stock, diluted34,455,11127,661,982

RXST Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 9,692$ 11,834
Short-term investments117,49093,968
Accounts receivable20,28110,956
Inventories17,42114,835
Prepaid and other current assets3,5232,962
Total current assets168,407134,555
Property and equipment, net10,84110,138
Operating leases right-of-use assets2,4443,943
Restricted cash711761
Other assets147767
Total assets182,550150,164
Current liabilities:  
Accounts payable3,8632,595
Accrued expenses and other current liabilities15,23912,672
Lease liabilities1,8011,970
Total current liabilities20,90317,237
Long-term lease liabilities1,2112,856
Term loan, net040,169
Other long-term liabilities740
Total liabilities22,18860,262
Commitments and contingencies (Note 9)
Stockholders' equity:  
Common stock, $0.001 par value, 900,000,000 shares authorized, 36,139,513 shares issued and outstanding as of December 31, 2023 and 28,268,389 Shares issued and outstanding as of December 31, 20223628
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding00
Additional paid-in capital754,971636,001
Accumulated other comprehensive loss(5)(95)
Accumulated deficit(594,640)(546,032)
Total stockholders' equity160,36289,902
Total liabilities and stockholders' equity$ 182,550$ 150,164
RXST
RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
 CEO
 WEBSITEwww.rxsight.com
 EMPLOYEES292

RxSight, Inc. Frequently Asked Questions


What is the ticker symbol for RxSight, Inc.? What does RXST stand for in stocks?

RXST is the stock ticker symbol of RxSight, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RxSight, Inc. (RXST)?

As of Wed Mar 27 2024, market cap of RxSight, Inc. is 1.87 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXST stock?

You can check RXST's fair value in chart for subscribers.

What is the fair value of RXST stock?

You can check RXST's fair value in chart for subscribers. The fair value of RxSight, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RxSight, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RXST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RxSight, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXST is over valued or under valued. Whether RxSight, Inc. is cheap or expensive depends on the assumptions which impact RxSight, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXST.

What is RxSight, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, RXST's PE ratio (Price to Earnings) is -38.56 and Price to Sales (PS) ratio is 21.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXST PE ratio will change depending on the future growth rate expectations of investors.